|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2001, Vol. 98, No. 1, pp. 201-209
NEOPLASIA
EAF1, a novel ELL-associated factor
that is delocalized by expression of the MLL-ELL
fusion protein
Federico Simone,
Paul E. Polak,
Joseph J. Kaberlein,
Roger T. Luo,
Denise A. Levitan, and
Michael
J. Thirman
From the Section of Hematology/Oncology, University of
Chicago, Chicago, IL.
The (11;19)(q23;p13.1) translocation in acute leukemia leads to the
generation of a chimeric protein that fuses MLL to the transcriptional
elongation factor ELL. A novel protein was isolated from a yeast
2-hybrid screen with ELL that was named EAF1 for ELL-associated factor
1. Using specific antibodies, the endogenous EAF1 and ELL proteins were
coimmunoprecipitated from multiple cell lines. In addition, endogenous
EAF1 also exhibited the capacity to interact with ELL2. Database
comparisons with EAF1 identified a region with a high content of
serine, aspartic acid, and glutamic acid residues that exhibited
homology with the transcriptional activation domains of several
translocation partner proteins of MLL, including AF4, LAF4, and AF5q31.
A similar transcriptional activation domain has been identified in this
region of EAF1. By confocal microscopy, endogenous EAF1 and ELL
colocalized in a distinct nuclear speckled pattern. Transfection of the
MLL-ELL fusion gene delocalized EAF1 from its nuclear
speckled distribution to a diffuse nucleoplasmic pattern. In leukemic
cell lines derived from mice transplanted with
MLL-ELL-transduced bone marrow, EAF1 speckles were not
detected. Taken together, these data suggest that expression of the
MLL-ELL fusion protein may have a dominant effect on the normal
protein-protein interactions of ELL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. R. Smith, B. Winter, J. C. Eissenberg, and A. Shilatifard
Regulation of the transcriptional activity of poised RNA polymerase II by the elongation factor ELL
PNAS,
June 24, 2008;
105(25):
8575 - 8579.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. S. Banks, S. E. Kong, H. Spahr, L. Florens, S. Martin-Brown, M. P. Washburn, J. W. Conaway, A. Mushegian, and R. C. Conaway
Identification and Characterization of a Schizosaccharomyces pombe RNA Polymerase II Elongation Factor with Similarity to the Metazoan Transcription Factor ELL
J. Biol. Chem.,
February 23, 2007;
282(8):
5761 - 5769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Kong, C. A. S. Banks, A. Shilatifard, J. W. Conaway, and R. C. Conaway
ELL-associated factors 1 and 2 are positive regulators of RNA polymerase II elongation factor ELL
PNAS,
July 19, 2005;
102(29):
10094 - 10098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. P. Yam, D.-Y. Jin, C. W. So, and L. C. Chan
Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein
Blood,
February 15, 2004;
103(4):
1445 - 1453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. Hackett, J. G. Hodgson, M. E. Law, J. Fridlyand, K. Osoegawa, P. J. de Jong, N. J. Nowak, D. Pinkel, D. G. Albertson, A. Jain, et al.
Genome-wide Array CGH Analysis of Murine Neuroblastoma Reveals Distinct Genomic Aberrations which Parallel those in Human Tumors
Cancer Res.,
September 1, 2003;
63(17):
5266 - 5273.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Xiao, Q. Zhang, F. Jiang, M. Pins, J. M. Kozlowski, and Z. Wang
Suppression of Prostate Tumor Growth by U19, a Novel Testosterone-regulated Apoptosis Inducer
Cancer Res.,
August 1, 2003;
63(15):
4698 - 4704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Saso, T. Ito, S. Natori, and K. Sekimizu
Identification of a Novel Tissue-Specific Transcriptional Activator FESTA as a Protein That Interacts with the Transcription Elongation Factor S-II
J. Biochem.,
April 1, 2003;
133(4):
493 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Polak, F. Simone, J. J. Kaberlein, R. T. Luo, and M. J. Thirman
ELL and EAF1 are Cajal Body Components That Are Disrupted in MLL-ELL Leukemia
Mol. Biol. Cell,
April 1, 2003;
14(4):
1517 - 1528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Simone, R. T. Luo, P. E. Polak, J. J. Kaberlein, and M. J. Thirman
ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties
Blood,
March 15, 2003;
101(6):
2355 - 2362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. W. Baron, J. Anastasi, M. J. Thirman, Y. Furukawa, S. Fears, D. C. Kim, F. Simone, M. Birkenbach, A. Montag, A. Sadhu, et al.
The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis
PNAS,
February 14, 2002;
(2002)
42702599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Luo, C. Lavau, C. Du, F. Simone, P. E. Polak, S. Kawamata, and M. J. Thirman
The Elongation Domain of ELL Is Dispensable but Its ELL-Associated Factor 1 Interaction Domain Is Essential for MLL-ELL-Induced Leukemogenesis
Mol. Cell. Biol.,
August 15, 2001;
21(16):
5678 - 5687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. W. Baron, J. Anastasi, M. J. Thirman, Y. Furukawa, S. Fears, D. C. Kim, F. Simone, M. Birkenbach, A. Montag, A. Sadhu, et al.
The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis
PNAS,
March 5, 2002;
99(5):
2860 - 2865.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
